Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302430 · ClinicalTrials.gov registry record · Phase 1
Intranasal Oxytocin and Enhancement of Team Cohesion
A Phase 1 study of Unit Cohesion, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 486
- Enrollment target
- 1
- Study location
NCT02302430: Completed Phase 1 study of Unit Cohesion, sponsored by University of California, San Francisco.
NCT02302430 is a Phase 1 study of Unit Cohesion that has completed, run by University of California, San Francisco. The registered enrollment target is 486 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (710% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02302430, a Phase 1 study of Unit Cohesion, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 486 participants
- Enrollment target
- 1
- Study location
Study Summary
This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.
Primary Outcome
Subjects will work together in groups of 2-4 performing a computer-based task flying a virtual plane.
Conditions Studied
Interventions
- DRUG Oxytocin
- OTHER Placebo comparator
Study Locations (1)
California
- San Francisco VA Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2015-10 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 1 |
What the finished NCT02302430 record still lists
NCT02302430 is an interventional study that assigns participants to a tested intervention. The registered 486 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (710% higher).
The record links to 1 condition, with Unit Cohesion appearing as the primary indexed condition, and to 2 interventions - of which Oxytocin is the first listed.
NCT02302430 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02302430 about?
NCT02302430 is a clinical study titled "Intranasal Oxytocin and Enhancement of Team Cohesion". This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of ...
What is the current status of trial NCT02302430?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 486 participants. The study started on 2015-10. Estimated completion is 2019-05-31.
What conditions does trial NCT02302430 study?
This clinical trial studies the following conditions: Unit Cohesion.
What interventions are being tested in trial NCT02302430?
The interventions under investigation include: Oxytocin (DRUG), Placebo comparator (OTHER).
Who is sponsoring clinical trial NCT02302430?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02302430 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02302430's enrollment target sits among peer trials
486 48th of 2000 higher than 1,953 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia